MEK inhibitors for the treatment of extracranial arteriovenous malformations  

作　　者：Zi’an Xu Jingwei Zhou Yuxi Chen Xi Yang Chen Hua Yunbo Jin Xiaoxi Lin 

机构地区：[1]Department of Plastic and Reconstructive Surgery,Shanghai Ninth People’s Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200011,China

出　　处：《Chinese Journal of Plastic and Reconstructive Surgery》2023年第3期141-144,共4页

基　　金：sponsored by 2023 Shanghai Jiao Tong University Medical-Industrial Intersection Key Project(grant no.YG2023ZD13):Screening of Novel Targeted Inhibitors Based on Genetic Vascular Malformation Organoid Models.

摘　　要：Arteriovenous malformations(AVMs)are serious congenital vascular anomalies in which the arteries connect directly with veins without capillaries.This condition will continue to worsen without proper intervention and cause ulcers,repeated hemorrhages,and even cardiac insufficiency.Primary treatment options for AVMs include surgery and interventional treatment;however,they are associated with high risk and recurrence rates.Recent studies revealed that excessive activation of the Ras/MAPK pathway can induce the formation and development of peripheral AVM,whereas MEK inhibitors can effectively control nidus progression,making them a potential novel treatment for AVM.This review provides an up-to-date overview of correlated laboratory and clinical research to provide information for further research and clinical practice.

关 键 词：Arteriovenous malformation MEK1 MEKi Trametinib MAPK 

分 类 号：R543[医药卫生—心血管疾病]